MNPHARM

company

About

Advancing Plant Based Medicine

  • 1 - 10

Details

Last Funding Type
Grant
Industries
Biotechnology
Founded date
Jan 1, 2015
Number Of Employee
1 - 10
Operating Status
Active

MNPHARM molecular farming combines technology advances in plant microbial genetic engineering, protein purification and controlled indoor agriculture to provide rapid access to affordable recombinant proteins.

MNPHARM is dedicated to producing human recombinant proteins needed in the field known as “Regenerative Medicine” to assist therapeutic development by lowering the cost of these proteins to the research community using our proprietary plant based protein expression methods.

Recombinant Human Bone Morphogenetic Protein 2 (rhBMP-2) is one of the proteins we produce and is shown to stimulate the production of bone, tissue and cartilage. MNPHARM is able to consistently express and purify large amounts of human recombinant BMP-2 at a purity of 97%+.

Compared to other means of protein production, our proprietary expression methods offers the lowest overall cost, short production times and exceptionally high quality.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
MNPHARM has raised a total of — in funding over 2 rounds. Their latest funding was raised on May 10, 2022 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
May 10, 2022 Grant 1 Regenerative Medicine Minnesota Detail

Investors

Number of Lead Investors
Number of Investors
1
1
MNPHARM is funded by 1 investors. Regenerative Medicine Minnesota are the most recent investors.
Investor Name Lead Investor Funding Round
Regenerative Medicine Minnesota Yes Grant